159 related articles for article (PubMed ID: 38177002)
21. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
22. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Zheng Y; Cao WM; Shao X; Shi Y; Cai L; Chen W; Liu J; Shen P; Chen Y; Wang X; Li H; Li M; Chen Z; Wang X
Nat Commun; 2023 Dec; 14(1):8314. PubMed ID: 38097605
[TBL] [Abstract][Full Text] [Related]
23. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.
Li F; Xu F; Li J; Wang T; Bian L; Zhang S; Jiang Z
Ann Transl Med; 2021 Jan; 9(2):103. PubMed ID: 33569405
[TBL] [Abstract][Full Text] [Related]
24. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
25. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
26. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
28. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
Yin W; Wang Y; Wu Z; Ye Y; Zhou L; Xu S; Lin Y; Du Y; Yan T; Yang F; Zhang J; Liu Q; Lu J
Clin Cancer Res; 2022 Sep; 28(17):3677-3685. PubMed ID: 35713517
[TBL] [Abstract][Full Text] [Related]
30. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
[TBL] [Abstract][Full Text] [Related]
31. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.
Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
[TBL] [Abstract][Full Text] [Related]
33. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
34. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH; Cercek A; Siena S; André T; Ng K; Van Cutsem E; Wu C; Paulson AS; Hubbard JM; Coveler AL; Fountzilas C; Kardosh A; Kasi PM; Lenz HJ; Ciombor KK; Elez E; Bajor DL; Cremolini C; Sanchez F; Stecher M; Feng W; Bekaii-Saab TS;
Lancet Oncol; 2023 May; 24(5):496-508. PubMed ID: 37142372
[TBL] [Abstract][Full Text] [Related]
35. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
37. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.
You S; Xie Y; Sang D; Luo T; Yuan P; Xu F; Wang B
Front Endocrinol (Lausanne); 2023; 14():1325540. PubMed ID: 38149099
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
Gu Q; Zhu M; Wang Y; Gu Y
Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
[TBL] [Abstract][Full Text] [Related]
40. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
You S; Sang D; Xu F; Luo T; Yuan P; Xie Y; Wang B
Ther Adv Med Oncol; 2023; 15():17588359231217972. PubMed ID: 38145113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
